Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer

(2014) E. Galanis et al.   CANCER RESEARCH

Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy

(2014) Stephen J. Russell et al.   MAYO CLINIC PROCEEDINGS

Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth

(2013) Hooi-Tin Ong et al.   JOURNAL OF HEPATOLOGY

Trial watch

(2013) Erika Vacchelli et al.   OncoImmunology

Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses

(2012) K-W Peng et al.   GENE THERAPY

Combination strategies for enhancing the efficacy of immunotherapy in cancer patients

(2010) Federica Moschella et al.   Annals of the New York Academy of Sciences